Non-Hodgkin lymphoma in women: Reproductive factors and exogenous hormone use

American Journal of Epidemiology

Volumn 168, Issue 3, 2008, Pages 278-288

  Lee, Jennifer S ^a,b   Bracci, Paige M ^c   Holly, Elizabeth A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Case control studies; Contraception; Estrogens; Hormone replacement therapy; Lymphoma, non Hodgkin; Menopause; Pregnancy; Reproduction

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

CANCER; COHORT ANALYSIS; CONTRACEPTIVE USE; HEALTH RISK; HORMONE; PREGNANCY; REGRESSION ANALYSIS; REPRODUCTION; RISK FACTOR; TUMOR;

ADULT; AGED; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLICULAR LYMPHOMA; FREQUENCY ANALYSIS; HORMONAL THERAPY; HUMAN; LARGE CELL LYMPHOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; POPULATION RISK; PREGNANCY; RANDOMIZATION; RISK REDUCTION; UNITED STATES;

ADULT; AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; LIFE STYLE; LOGISTIC MODELS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; ODDS RATIO; PREGNANCY; QUESTIONNAIRES; REPRODUCTIVE HISTORY; RISK FACTORS; SAN FRANCISCO; SEER PROGRAM;

CALIFORNIA; NORTH AMERICA; SAN FRANCISCO BAY; UNITED STATES;

EID: 47649120166     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn119     Document Type: Article

References (49)

1. Hartge P, Wang SS, Bracci PM, et al. Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 3rd ed. New York, NY: Oxford University Press, 2006.
2. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51.
3. Zhang Y, Holford TR, Leaderer B, et al. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. Am J Epidemiol 2004;160:766-73.
4. Preti HA, Cabanillas F, Talpaz M, et al. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997;127:186-94.
5. Kincade PW, Medina KL, Payne KJ, et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000;175:128-37.
6. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000;95:2059-67.
7. Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004;113:224-30.
8. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996;17:369-84.
9. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001;19:1381-7.
10. Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2002;11:1466-71.
11. Skibola CF, Bracci PM, Paynter RA, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005;14:2391-401.
12. Holly EA, Gautam M, Bracci PM. Comparison of interviewed and non-interviewed non-Hodgkin's lymphoma (NHL) patients in the San Francisco Bay Area. Ann Epidemiol 2002;12:419-25.
13. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
14. Holly EA, Lele C. Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area: allergies, prior medication use, and sexual practices. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:211-22.
15. Holly EA, Lele C, Bracci P. Non-Hodgkin's lymphoma in homosexual men in the San Francisco Bay Area: occupational, chemical, and environmental exposures. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:223-31.
16. Holly EA, Lele C, Bracci PM, et al. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150:375-89.
17. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 2003;158:316-27.
18. Bracci PM, Holly EA. Tobacco use and non-Hodgkin lymphoma: results from a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control 2005;16:333-46.
19. Bracci PM, Dalvi TB, Holly EA. Residential history, family characteristics and non-Hodgkin lymphoma, a population-based case-control study in the San Francisco Bay Area. Cancer Epidemiol Biomarkers Prev 2006;15:1287-94.
20. Flick ED, Chan KA, Bracci PM, et al. Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol 2006;164:497-504.
21. Nichols HB, Trentham-Dietz A, Hampton JM, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol 2006;164:1003-11.
22. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28.
23. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120(suppl 12):1-39.
24. Cerhan JR, Habermann TM, Vachon CM, et al. Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). Cancer Causes Control 2002;13:131-6.
25. Adami HO, Tsaih S, Lambe M, et al. Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study. Int J Cancer 1997;70:155-8.
26. Tavani A, Pregnolato A, La Vecchia C, et al. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 1997;21:885-8.
27. Altieri A, Gallus S, Franceschi S, et al. Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev 2004;13:349-51.
28. Beiderbeck AB, Holly EA, Sturkenboom MC, et al. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639-44.
29. Fernandez E, Gallus S, Bosetti C, et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408-12.
30. Schiff D, Suman VJ, Yang P, et al. Risk factors for primary central nervous system lymphoma: a case-control study. Cancer 1998;82:975-82.
31. Cerhan JR, Wallace RB, Folsom AR, et al. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997;89:314-18.
32. Medina KL, Kincade PW. Pregnancy-related steroids are potential negative regulators of B lymphopoiesis. Proc Natl Acad Sci U S A 1994;91:5382-6.
33. Kincade PW, Medina KL, Smithson G, et al. Pregnancy: a clue to normal regulation of B lymphopoiesis. Immunol Today 1994;15:539-44.
34. Kincade PW, Medina KL, Smithson G. Sex hormones as negative regulators of lymphopoiesis. Immunol Rev 1994;137:119-34.
35. Auerbach L, Hafner T, Huber JC, et al. Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle. Fertil Steril 2002;78:83-9.
36. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003;21:3352-7.
37. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-8.
38. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003;38:13-22.
39. Pietschmann P, Gollob E, Brosch S, et al. The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 2003;38:1119-27.
40. Stopinska-Gluszak U, Waligora J, Grzela T, et al. Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women. J Reprod Immunol 2006;69:65-75.
41. Deguchi K, Kamada M, Irahara M, et al. Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause 2001;8:266-73.
42. Kamada M, Irahara M, Maegawa M, et al. B cell subsets in postmenopausal women and the effect of hormone replacement therapy. Maturitas 2001;37:173-9.
43. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997;26:251-9.
44. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
45. Rachon D, Mysliwska J, Suchecka-Rachon K, et al. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 2002;172:387-95.
46. Saucedo R, Rico G, Basurto L, et al. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstet Invest 2002;53:114-17.
47. Berg G, Ekerfelt C, Hammar M, et al. Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am J Reprod Immunol 2002;48:63-9.
48. Savage KJ, Gascoyne RD. Molecular signatures of lymphoma. Int J Hematol 2004;80:401-9.
49. Krause JR, Shahidi-Asl M. Molecular pathology in the diagnosis and treatment of non-Hodgkin's lymphomas. J Cell Mol Med 2003;7:494-512.